All In Biotech

Drug Trial Radar · NCT07933692

Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation Stroke

A Multicenter Randomized Controlled Trial Study of the Effect of Edaravone and Dexcamphan on the Repair of Blood-brain Barrier Injury in Acute Infarction of Anterior Circulation

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 432 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

432

Planned (sponsor's estimate)

Start

Oct 1, 2021

Primary completion

Dec 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Shandong Provincial HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Dongying People's Hospital; Zibo Central Hospital; Heze Municipal Hospital; Shengli Oilfield Hospital; Liaocheng People's Hospital; Tengzhou Central People's Hospital; Shandong Province Third hospital; Zaozhuang Municipal Hospital
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 35 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter randomized controlled trial evaluates the effect of edaravone dexborneol on blood-brain barrier repair in patients with acute anterior circulation large artery atherosclerotic ischemic stroke within 48 hours of onset. Patients are randomized 1:1 to receive either edaravone dexborneol (30mg/7.5mg BID IV) or edaravone (30mg BID IV) for 9±2 days, in addition to standard stroke treatment. The primary outcome is the change in blood-brain barrier permeability (Ktrans) measured by DCE-MRI. Secondary outcomes include neurological function scores, serum biomarkers, and safety events.

Conditions

  • Acute Ischemic Stroke

Interventions

  • EdaravoneDrug

    Edaravone 30 mg administered by intravenous drip twice daily (BID) for 9±2 days, in addition to standard guideline-based treatment for acute ischemic stroke.

  • Edaravone DexborneolDrug

    Edaravone dexborneol (30 mg/7.5 mg) administered by intravenous drip twice daily (BID) for 9±2 days, in addition to standard guideline-based treatment for acute ischemic stroke.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Ktrans (blood-brain barrier permeability) measured by DCE-MRITime frame: From baseline (24-48 hours after stroke onset) to day 9±2 after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shandong Provincial Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.